Tactile Systems Technology reported second quarter 2026 results with total revenue increasing 9% year-over-year to $85.7 million and net income rising to $7.8 million, or $0.34 per diluted share, compared to $3.2 million in the prior year period. The company updated its full-year 2026 financial outlook, lowering total revenue guidance to a range of $360 million to $366 million while maintaining adjusted EBITDA expectations between $49 million and $51 million. Management cited temporary inventory management dynamics associated with the launch of the next-generation AffloVest system as a factor in the revised airway clearance product line outlook. Additionally, Tactile repurchased $5.3 million of stock during the quarter and entered into an exclusive U.S. distribution agreement for its MyoSleeve device.

Tactile Systems Technology, Inc. entered into an exclusive U.S. distribution agreement with ElastiMed, Inc. to market the MyoSleeve wearable compression device to Department of Veterans Affairs and Department of Defense patients. The company made an upfront payment of $3 million to ElastiMed and committed to minimum purchase obligations and marketing support. Tactile Systems Technology, Inc. develops and manufactures medical technology solutions for chronic swelling management.